Advertisement
UK markets close in 8 hours 23 minutes
  • FTSE 100

    8,354.05
    0.00 (0.00%)
     
  • FTSE 250

    20,491.99
    0.00 (0.00%)
     
  • AIM

    779.83
    0.00 (0.00%)
     
  • GBP/EUR

    1.1621
    -0.0002 (-0.01%)
     
  • GBP/USD

    1.2481
    -0.0016 (-0.13%)
     
  • Bitcoin GBP

    49,366.04
    -747.88 (-1.49%)
     
  • CMC Crypto 200

    1,311.55
    +11.45 (+0.88%)
     
  • S&P 500

    5,187.67
    -0.03 (-0.00%)
     
  • DOW

    39,056.39
    +172.13 (+0.44%)
     
  • CRUDE OIL

    79.34
    +0.35 (+0.44%)
     
  • GOLD FUTURES

    2,320.90
    -1.40 (-0.06%)
     
  • NIKKEI 225

    38,073.98
    -128.39 (-0.34%)
     
  • HANG SENG

    18,520.40
    +206.54 (+1.13%)
     
  • DAX

    18,498.38
    +68.33 (+0.37%)
     
  • CAC 40

    8,131.41
    0.00 (0.00%)
     

Investing in Physicians Realty Trust (NYSE:DOC) three years ago would have delivered you a 31% gain

Low-cost index funds make it easy to achieve average market returns. But in any diversified portfolio of stocks, you'll see some that fall short of the average. Unfortunately for shareholders, while the Physicians Realty Trust (NYSE:DOC) share price is up 11% in the last three years, that falls short of the market return. Zooming in, the stock is actually down 0.9% in the last year.

So let's investigate and see if the longer term performance of the company has been in line with the underlying business' progress.

Check out our latest analysis for Physicians Realty Trust

While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.

ADVERTISEMENT

Physicians Realty Trust was able to grow its EPS at 3.5% per year over three years, sending the share price higher. Notably, the 4% average annual share price gain matches up nicely with the EPS growth rate. That suggests that the market sentiment around the company hasn't changed much over that time. Rather, the share price has approximately tracked EPS growth.

You can see how EPS has changed over time in the image below (click on the chart to see the exact values).

earnings-per-share-growth
earnings-per-share-growth

It might be well worthwhile taking a look at our free report on Physicians Realty Trust's earnings, revenue and cash flow.

What About Dividends?

As well as measuring the share price return, investors should also consider the total shareholder return (TSR). The TSR incorporates the value of any spin-offs or discounted capital raisings, along with any dividends, based on the assumption that the dividends are reinvested. Arguably, the TSR gives a more comprehensive picture of the return generated by a stock. In the case of Physicians Realty Trust, it has a TSR of 31% for the last 3 years. That exceeds its share price return that we previously mentioned. This is largely a result of its dividend payments!

A Different Perspective

Physicians Realty Trust provided a TSR of 4.4% over the last twelve months. Unfortunately this falls short of the market return. On the bright side, the longer term returns (running at about 6% a year, over half a decade) look better. Maybe the share price is just taking a breather while the business executes on its growth strategy. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Take risks, for example - Physicians Realty Trust has 3 warning signs (and 1 which is a bit unpleasant) we think you should know about.

Of course Physicians Realty Trust may not be the best stock to buy. So you may wish to see this free collection of growth stocks.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.